Winnow Wealth LLC Makes New Investment in Hims & Hers Health, Inc. $HIMS

Winnow Wealth LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 21,302 shares of the company’s stock, valued at approximately $1,214,000. Hims & Hers Health accounts for approximately 1.0% of Winnow Wealth LLC’s investment portfolio, making the stock its 17th biggest holding.

Several other institutional investors have also recently made changes to their positions in HIMS. Quent Capital LLC purchased a new stake in Hims & Hers Health during the third quarter valued at approximately $28,000. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth $29,000. Bessemer Group Inc. raised its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the period. Finally, Hilltop National Bank purchased a new position in Hims & Hers Health during the third quarter valued at $35,000. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Evercore ISI began coverage on Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target for the company. Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a report on Monday, January 5th. Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, KeyCorp began coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $44.54.

Hims & Hers Health Trading Down 9.1%

Hims & Hers Health stock opened at $27.15 on Friday. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The firm’s 50 day moving average price is $34.34 and its 200-day moving average price is $44.35. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The stock has a market cap of $6.18 billion, a P/E ratio of 50.28, a PEG ratio of 4.92 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s revenue was up 49.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 earnings per share. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has initiated a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. The trade was a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 131,974 shares of company stock valued at $4,763,800 in the last 90 days. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.